Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi. Vinod K VK
Key Findings
- Standard peginterferon‑ribavirin therapy only works in about half of treatment‑naïve hepatitis C patients.
- Combining thymalfasin with peginterferon‑alpha2a improved response rates in difficult‑to‑treat genotype 1 patients.
- Adding ribavirin to the thymalfasin and peginterferon combo showed further promising results in the same high‑risk group.
Practical Outcomes
- For biohackers who have chronic hepatitis C, thymalfasin may be a useful adjunct to boost standard antiviral therapy, but it requires prescription and medical oversight. It isn’t a general longevity supplement and its benefits are limited to specific HCV cases.
Summary
Thymosin‑alpha1 (thymalfasin) added to the usual hepatitis C drugs (peginterferon‑alpha2a, sometimes ribavirin) helped patients who normally don’t respond well, especially those with genotype 1, high virus levels, or past treatment failures.
Abstract
Approximately 50% of treatment-naive hepatitis C patients fail to achieve a sustained virologic response with standard peginterferon and ribavirin therapy. Patients who are infected with genotype 1 have high viral loads and are nonresponders to previous therapy, and are even more difficult to treat, underscoring the need for new therapeutic options. Thymalfasin (thymosin-alpha1), in combination with peginterferon-alpha2a, has demonstrated efficacy among difficult-to-treat patients with hepatitis C. The addition of ribavirin to thymalfasin and peginterferon-alpha2a has also exhibited promising results among patients who have genotype 1 hepatitis C, high viral loads and are nonresponders to previous therapy.
Study Information
pubmed
2005
2005-12-01T00:00:00.000Z
10.1586/14787210.3.6.885
9
30